Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 215-113-2 | CAS number: 1302-93-8
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Link to relevant study record(s)
Description of key information
Key value for chemical safety assessment
- Bioaccumulation potential:
- no bioaccumulation potential
Additional information
Toxicokinetics of Mullite constituents
Summary of Aluminium toxicokinetics
In experimental animals, absorption of aluminium via the gastrointestinal tract is usually less
than 1%. The main factors influencing absorption are the chemical structure, solubility and pH.
Organic complex forming compounds, notably citrate, increase absorption.
Aluminium absorption may interact with calcium and iron transport systems.
Aluminium, once absorbed, is distributed in most organs within the body, with accumulation occurring mainly in bone at high dose levels.
To a limited but as yet undetermined extent, aluminium passes the blood–brain barrier and is also distributed to the fetus. Aluminium is eliminated effectively in urine.
In humans, aluminium and its compounds appear to be poorly absorbed, although the rate and extent of absorption have not been adequately studied. The mechanism of gastrointestinal absorption has not yet been fully elucidated. Variability results from the chemical properties of the element and the formation of various chemical species, which is dependent upon the pH, ionic strength, presence of competing elements (e.g. silicon), and presence of complex forming agents within the gastrointestinal tract (e.g. citrate). The urine is the most important route of aluminium excretion.
Steady state serum to whole blood aluminium concentrations are approximately equal. Slightly above 90% of plasma aluminium is associated with transferrin (Tf), ca. 7 to 8% with citrate, and less than 1% with phosphate and hydroxide.
Normal plasma aluminium concentration is believed to be 1 to 2μg/L. Normal tissue aluminium concentrations are greater in lung (due to entrapment of particles from the environment) than bone than soft tissues.
Approximately 60, 25, 10, 3 and 1% of the aluminium body burden is in the bone, lung, muscle, liver and brain, respectively.
Higher concentrations are observed in uraemia and they are still higher in dialysis encephalopathy.
Tissue aluminium concentration increases with age. Some studies have reported that the aluminium concentrations in bulk brain samples, neurofibrillary tangles (NFT) and
plaques were higher in AD subjects than controls. Other studies have found no difference.Hair aluminium concentration has been described but its value as an indicator of aluminium body burden has not been demonstrated.
More than 95% of aluminium is eliminated by the kidneys and ca. 2% in bile.
Occupational aluminium exposure increases urinary aluminium concentrations more than in plasma concentration above their normal levels.
Depending on the type and route of exposure, aluminium clearance has been characterized to obviously have multiple half-times and is therefore estimated in hours, days and years. Most of the Aluminium was eliminated within the first week; the terminal half-life probably represents less than 1% of the injected aluminium.
Source:
1) Background document for development of WHOGuidelines for Drinking-water Quality,
WHO/SDE/WSH/03.04/53
2) „HUMAN HEALTH RISK ASSESSMENT FOR ALUMINIUM, ALUMINIUM OXIDE, AND
ALUMINIUM HYDROXIDE“,Daniel Krewski, Robert A Yokel, Evert Nieboer, David
Borchelt, Joshua Cohen, Jean Harry7, Sam Kacew, Joan Lindsay, Amal M Mahfouz,
Virginie Rondeau; available at:http://www.world-aluminium.org/cache/fl0000237.pdf
Summary of Silicon toxicokinetics
Distribution and metabolism
Silicon is a component of serum, being present in the form of non proteinbound orthosilicic acid. Its metabolic pathways are only partially understood. Silicic acid is thought to be the form present in blood.
The highest silicon levels, among human tissues, are found in the walls of the aorta, tendons, aponeuroses and skin. In dialysis patients silicon has been found in the liver, spleen and lung.
In rats given intra-cardiac injections of 31silicon labelled silicic acid, one hour after dosing the highest levels were found in the kidney, liver and lungs with moderate amounts being found in bone, skin, muscle, testes and spleen. The levels then began to decline when measured 2 and 4 hours after dosing Brain tissue contained negligible amounts of silicon suggesting active exclusion by the blood-brain barrier.
Silicon can be detected in small areas of ossifying bone during the early stages of mineralisation. The silicon content of young osteoid tissue increases markedly, together with that of calcium, but at more advanced stages of bone formation, when calcification sets in, the silicon content decreases again to trace levels. The element is located within the mitochondria of the osteoblast.
It has been shown that silicon concentrations in human arteries decrease with increasing age and with the onset of atherosclerosis. Several reports have independently confirmed a decline in silicon with age in some animal tissues, but ist causes and possible relevance to the ageing process remain unknown.
Excretion
The kidneys play the main role in silicon excretion. It is excreted in urine in the form of the orthosilicic anion bound mainly with magnesium or calcium cations. Significant correlations
were observed between creatinine clearance and silicon levels in serum and urine. Renal clearance was 82-96 ml/min suggesting high renal filterability.
In patients suffering from chronic renal failure, urinary silicon excretion was decreased and serum silicon levels increased. Silicon excretion was not increased in 391 patients with renal stones compared to 370 healthy controls and no relationship with calcium or oxalate excretion was apparent.
Elimination of radiolabelled silicic acid in a human volunteer indicated two simultaneous first-order processes with half lives of 2.7 and 11.3 hours respectively. Elimination was essentially complete after 48 hours and was equivalent to 36% of the dose given. 90% of the absorbed silicon was rapidly eliminated and was probably retained in the extracellular fluid volume while the slowly eliminated silicon could represent intra-cellular silicon.
Silicon is also excreted, in smaller quantities, via the faeces.
Source:
Expert Group on Vitamins and Minerals Secretariat, August 2002, available at:http://www.food.gov.uk/multimedia/pdfs/evm0107p.pdf
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.